Trends in long-term survival of patients with chronic lymphocytic leukemia from the 1980s to the early 21st century

Blood ◽  
2008 ◽  
Vol 111 (10) ◽  
pp. 4916-4921 ◽  
Author(s):  
Hermann Brenner ◽  
Adam Gondos ◽  
Dianne Pulte
Keyword(s):  
Chronic Lymphocytic Leukemia ◽  
Relative Survival ◽  
The United States ◽  
Lymphocytic Leukemia ◽  
Term Survival ◽  
Long Term Survival ◽  
Early 21St Century ◽  
Percentage Points ◽  
Survival Expectations

Abstract Although chronic lymphocytic leukemia (CLL) has remained incurable with standard treatments, newer therapeutic approaches, such as chemoimmunotherapy or stem cell transplantation, bear the potential for prolonged survival. We estimated trends in age-specific 5- and 10-year absolute and relative survival of CLL patients in the United States between 1980-1984 and 2000-2004 from the 1973 to 2004 database of the Surveillance, Epidemiology, and End Results Program. Period analysis was used to disclose recent developments with minimum delay. Overall, 5- and 10-year absolute survival from diagnosis increased from 54.2% to 60.2% (+6 percentage points; P < .0001) and from 27.8% to 34.8% (+7 percentage points; P < .0001), respectively. Despite a strong age gradient in prognosis, increases in 5-year absolute and relative survival over time were rather homogeneous across age groups. In contrast, increases in 10-year absolute and relative survival close to or well above 10% units were observed for all patients younger than 80 years of age at diagnosis compared with no increase at all for older patients. Long-term survival expectations of patients with CLL have substantially improved over the past 2 decades except for patients 80 years of age or older at the time of diagnosis. Future studies are needed to confirm and expand our findings.

scholarly journals No improvement in long-term survival over time for chronic lymphocytic leukemia patients in stereotyped subsets #1 and #2 treated with chemo(immuno)therapy

Haematologica ◽  
2017 ◽  
Vol 103 (4) ◽  
pp. e158-e161 ◽  
Author(s):  
Panagiotis Baliakas ◽  
Mattias Mattsson ◽  
Anastasia Hadzidimitriou ◽  
Eva Minga ◽  
Andreas Agathangelidis ◽  
...  
Keyword(s):  
Chronic Lymphocytic Leukemia ◽  
Lymphocytic Leukemia ◽  
Term Survival ◽  
Long Term Survival ◽  
Over Time

scholarly journals Long-term survival after fludarabine, cyclophosphamide, and rituximab treatment in previously untreated chronic lymphocytic leukemia patients

2021 ◽  
Vol 10 (2) ◽  
pp. 139
Author(s):  
ShokhanMohammad Mustafa ◽  
AhmedKhudair Yassin ◽  
NawsherwanS Mohammed ◽  
RawandP Shamoon ◽  
MarwaN Karam ◽  
...  
Keyword(s):  
Chronic Lymphocytic Leukemia ◽  
Lymphocytic Leukemia ◽  
Term Survival ◽  
Long Term Survival

scholarly journals Prolonged response to liposomal irinotecan in a patient with stage IV pancreatic/bile duct cancer previously treated with FOLFIRINOX and gemcitabine plus nab-paclitaxel

2019 ◽  
Vol 27 (2) ◽  
Author(s):  
A. Surinach ◽  
T. Phung ◽  
O. Abdul-Rahim ◽  
M. Khushman
Keyword(s):  
Bile Duct ◽  
Karnofsky Performance Status ◽  
Stage Iv ◽  
Relative Survival ◽  
The United States ◽  
Ductal Adenocarcinoma ◽  
Term Survival ◽  
Long Term Survival ◽  
Liposomal Irinotecan

At 9%, and 2% when diagnosed at advanced stage, the 5-year relative survival rate for pancreatic ductal adenocarcinoma (pdac) is the lowest of any cancer. The currently approved treatment options for metastatic pdac in the United States are folfirinox [irinotecan–fluorouracil (5fu)–leucovorin (lv)–oxaliplatin], gemcitabine–nab-paclitaxel, and liposomal irinotecan plus 5fu–lv. Liposomal irinotecan is a novel formulation of irinotecan encapsulated within a lipid bilayer, which favours localmetabolic activation. The napoli-1 trial demonstrated the efficacy of liposomal irinotecan in combination with 5fu and lv for the treatment of advanced pdac after progression on gemcitabine-based chemotherapy. The 1-year survival in those patients was 25%; however, none had had irinotecan-refractory disease before treatment with liposomal irinotecan. Furthermore, the U.S. National Comprehensive Cancer Network guidelines recommend liposomal irinotecan plus 5fu–lv in patients who have received prior fluoropyrimidine-based therapy if no prior irinotecan therapy has been given. Here, we report a male patient with stage iv cancer of pancreas or bile duct (site unconfirmed) who experienced a prolonged (51 weeks) response to liposomal irinotecan plus 5fu–lv despite prior disease progression on irinotecan. Several factors have previously been associated with long-term survival in patients receiving liposomal irinotecan therapy: no prior irinotecan-based chemotherapy, high Karnofsky performance status score, age 65 years or less, serum carbohydrate antigen 19-9 less than 59 U/mL, neutrophil-to-lymphocyte ratio 5 or less, and absence of liver metastasis. The patient in the present report had none of those characteristics indicative of long-term survival, except his age at diagnosis—47 years.

Long-term survival in chronic lymphocytic leukemia after first primary malignancy in the United States.

2017 ◽  
Vol 35 (15_suppl) ◽  
pp. e18090-e18090
Author(s):  
Amir Bista ◽  
Dipesh Uprety ◽  
Subash Ghimire ◽  
Megha Giri ◽  
Binay Kumar Shah
Keyword(s):  
Chronic Lymphocytic Leukemia ◽  
Relative Survival ◽  
The United States ◽  
Lymphocytic Leukemia ◽  
Second Primary ◽  
Age Group ◽  
Primary Cancer ◽  
Primary Malignancy ◽  
Term Survival ◽  
Cancer Breast

e18090 Background: There has been significant improvement in survival among patients with primary Chronic Lymphocytic Leukemia (CLL) in recent years but, not much is known about survival among CLL developed after a first primary malignancy. Methods: SEER 18 database, 2015 submission, was used to calculate 5 and 10 year relative survival (RS) by period survival modeling method for 1993 to 2012, with division of the period into 4 cohorts of 5 years each. SEER*Stat software from National Cancer Institute was used to calculate relative survival (RS) for 4 different periods of 5 years duration. The trend in survival for cases with CLL as second primary cancer (CLLSPC) was evaluated using COX proportional hazard method using Cansurv software and also compared with that of primary CLL cases. Results: A total of 8731 patients with CLLSPC were included in the study, which represents 14.5% of all cases of CLL. The median age at diagnosis was 75 years. Median time to diagnosis of CLL was 50 months after diagnosis of first primary malignancy. Prostate cancer, breast cancer and colorectal cancer were 3most common primary cancers. 5-year and 10-year RS improved significantly in the year 2008-2012 compared to 1993-1997 (59.3% to 70.2%,P 0.044 and 40.1% to 50.6%, p 0.045). In subgroup analysis, significant improvement in 5-year and 10-year RS was seen in females and ≥ 80 years age group but no significant improvement was observed in males and age group 60-79 years. Survival among CLLSPC was significant worse compared to first primary CLL in all periods, even after adjusting for age and sex. Conclusions: CLLSPC represents about 14.5% of all CLL cases. Relative survival among patients with CLLSPC is gradually improving but still lags behind that of CLL as first primary cancer.

Recent major improvement in long-term survival of younger patients with multiple myeloma

Blood ◽  
2008 ◽  
Vol 111 (5) ◽  
pp. 2521-2526 ◽  
Author(s):  
Hermann Brenner ◽  
Adam Gondos ◽  
Dianne Pulte
Keyword(s):  
Multiple Myeloma ◽  
Relative Survival ◽  
The United States ◽  
Age Group ◽  
Term Survival ◽  
Period Analysis ◽  
Younger Patients ◽  
Long Term Survival ◽  
The Past

In the past, most patients with multiple myeloma (MM) died within 5 to 10 years after diagnosis. Within the past decade, several new therapeutic interventions have been introduced, including autologous stem-cell transplantation, thalidomide, lenalidomide, and bortezomib. We estimated trends in age-specific 5- and 10-year relative survival of patients with MM in the United States from 1990-1992 to 2002-2004 from the 1973-2004 database of the Surveillance, Epidemiology, and End Results (SEER) Program. Techniques of period analysis were used to show most recent developments. Overall, 5-year relative survival increased from 28.8% to 34.7% (P < .001), and 10-year relative survival increased from 11.1% to 17.4% (P < .001) between 1990-1992 and 2002-2004. Much stronger increases were seen in the age group younger than 50 years, leading to 5- and 10-year relative survival of 56.7% and 41.3% in 2002-2004, and in the age group 50 to 59 years, leading to 5- and 10-year relative survival of 48.2% and 28.6% in 200-2004. By contrast, only moderate improvement was seen in the age group 60 to 69 years, and essentially no improvement was achieved among older patients. Our period analysis discloses a major increase in long-term survival of younger patients with MM in recent years, which most likely reflects the effect of recent advances in therapy and their dissemination in clinical practice.

Ongoing improvement in long-term survival of patients with Hodgkin disease at all ages and recent catch-up of older patients

Blood ◽  
2008 ◽  
Vol 111 (6) ◽  
pp. 2977-2983 ◽  
Author(s):  
Hermann Brenner ◽  
Adam Gondos ◽  
Dianne Pulte
Keyword(s):  
Older Patients ◽  
Relative Survival ◽  
Population Level ◽  
The United States ◽  
Hodgkin Disease ◽  
Term Survival ◽  
Period Analysis ◽  
Long Term Survival ◽  
The 1960S

Abstract Since the breakthroughs in combination chemotherapy of patients with Hodgkin disease (HD) starting in the 1960s, prognosis of patients has been rising steadily. Trends in long-term survival of patients with HD on the population level should therefore be monitored in an as timely as possible manner. We assessed trends in age specific 5- and 10-year relative survival of patients with HD in the United States from 1980-1984 to 2000-2004 from the 1973-2004 database of the Surveillance, Epidemiology, and End Results (SEER) Program. Period analysis was used to disclose recent developments with minimum delay. Overall, 5-year relative survival steadily increased from 73.5% to 85.2% (+11.7 percentage units), and 10-year relative survival increased from 62.1% to 80.1% (+18.0 percentage units) between 1980-1984 and 2000-2004, according to period analysis. The increase was particularly pronounced for patients aged 45 to 59 years and 60 years and older (increases in 10-year relative survival by 24.8 and 23.3 percentage points, respectively). Nevertheless, a strong age gradient persisted, with 10-year relative survival of 92.7%, 88.7%, 84.9%, 76.2%, and 44.9% in patients aged 15 to 24 years, 25 to 34 years, 35 to 44 years, 45 to 54 years, and 60 years and older, respectively, in 2000-2004. Our period analysis discloses ongoing, major improvement in long-term survival of patients with HD in recent years, particularly among older patients.

Expected Long-Term Survival of Patients Diagnosed with Multiple Myeloma in 2006–2010

Blood ◽  
2008 ◽  
Vol 112 (11) ◽  
pp. 2368-2368
Author(s):  
Hermann Brenner ◽  
Adam Gondos ◽  
Dianne Pulte
Keyword(s):  
Multiple Myeloma ◽  
Survival Analysis ◽  
Cohort Analysis ◽  
Empirical Evaluation ◽  
Relative Survival ◽  
Term Survival ◽  
Long Term Survival ◽  
Model Based ◽  
Survival Expectations

Abstract Background: New therapeutic options have led to substantial increases in survival expectations of patients with multiple myeloma (MM) in recent years. In the past, the impact of these innovations on long-term survival of MM patients on the population level has been disclosed only with substantial delay, partly due to delayed availability of data from population-based cancer registries. Methods: Using data from the 1973–2005 database of the Surveillance, Epidemiology, and End Results (SEER) Program, we employed a novel model-based projection method to project 5-and 10-year relative survival expectations of MM patients in the United States diagnosed in 2006 to 2010, after conducting an empirical evaluation of the method using data from patients diagnosed between 1996 and 2000 (the last cohort for which 5-year follow up is available through SEER) and earlier years. Results: Preliminary empirical evaluation of the method using historical data indicates good performance in projection of age specific and overall 5- and 10-year relative survival. Model based projection of survival produced survival estimates that matched observed survival estimates more closely than cohort analysis or period analysis, the standard methods of survival analysis, in 21 out of 24 cases. The average difference from observed was −1.27 percentage units for model based projection, −3.71 percentage units for period analysis, and −4.23 percentage units for cohort analysis. Five-year relative survival projections for patients diagnosed in 2006–2010 at ages 15–49 and 50–59 are 61.4% and 52.0% (see table), respectively, and exceed the most up-to-date estimates obtained from traditional cohort analysis by 9.5 and 6.9 percent units, respectively. Ten-year relative survival projections for patients in these age groups are 47.1% and 30.4%, exceeding the most up-to-date estimates from traditional cohort analysis by 13.5 and 9.6 percent units, respectively. By contrast, survival projections remain much lower and hardly exceed estimates from traditional survival analysis for older patients. Conclusions: The use of model based projection results in more up-to-date estimates of survival than standard methods of survival analysis. Patients diagnosed with multiple myeloma in 2006–2010 have much higher long-term survival expectations than suggested by previously available survival statistics. Table: Most up-to-date estimates of 5-year and 10-year relative survival of patients diagnosed with multiple myeloma obtained by different methods. Age Cohort estimates* Period estimates for 2001–2005 period Projections for patients diagnosed in 2006–2010 PE SE PE SE PE SE * The most up-to-date cohort estimates of 5-year survival pertain to patients diagnosed in 1996–2000, and the most up-to-date cohort estimates of 10-year survival pertain to patients diagnosed in 1991–1995. 5-year relative survival 15+ 32.1 0.7 34.2 0.7 36.1 1.0 15–49 51.9 2.3 56.4 2.2 61.4 3.1 50–59 45.1 1.7 48.0 1.6 52.0 2.3 60–69 33.8 1.4 36.5 1.4 36.7 2.0 70–79 27.4 1.2 26.7 1.2 27.9 1.7 80+ 13.2 1.4 14.1 1.4 16.4 1.9 10-year relative survival 15+ 14.1 0.6 16.6 0.6 18.0 0.8 15–49 33.6 2.2 40.3 2.4 47.1 3.2 50–59 20.8 1.6 27.0 1.7 30.4 2.3 60–69 12.4 1.0 15.0 1.2 15.4 1.4 70–79 8.8 1.0 8.9 0.9 9.9 1.1 80+ 6.4 1.6 5.9 1.4 6.6 1.4

Sign in / Sign up

Export Citation Format

Share Document